Decitabine in Acute Myeloid Leukemia

Aoki, 2000, Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes, Leukemia, 14, 586, 10.1038/sj.leu.2401719 Claus, 2003, Epigenetic targets in hematopoietic malignancies, Oncogene, 22, 6489, 10.1038/sj.onc.1206814 Creusot, 1982, Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine, J Biol Chem, 257, 2041, 10.1016/S0021-9258(19)68144-5 de Lima, 2003, Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias, Cancer, 97, 1242, 10.1002/cncr.11184 Di Croce, 2002, Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor, Science, 295, 1079, 10.1126/science.1065173 Galm, 2005, Aberrant DNA methylation patterns in acute myelogenous leukemia, Ann Hematol, 10.1007/s00277-005-0005-0 Garcia-Manero, 2004, Results of a phase I/II study of the combination of 5-aza-2′-deoxycytidine (DAC) and valproic acid (VPA) in patients with leukemia, Blood, 104, 263a, 10.1182/blood.V104.11.263.263 Issa, 2004, Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies, Blood, 103, 1635, 10.1182/blood-2003-03-0687 Jones, 1980, Cellular differentiation, cytidine analogs and DNA methylation, Cell, 20, 85, 10.1016/0092-8674(80)90237-8 Kuendgen, 2004, Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid, Blood, 104, 1266, 10.1182/blood-2003-12-4333 Liu, 2005, Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia, Cancer Res, 65, 1277, 10.1158/0008-5472.CAN-04-4532 Löwenberg, 1989, On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia, J Clin Oncol, 7, 1268, 10.1200/JCO.1989.7.9.1268 Lübbert, 2001, Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine, Br J Haematol, 114, 349, 10.1046/j.1365-2141.2001.02933.x Momparler, 1985, Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia, Pharmacol Ther, 30, 277, 10.1016/0163-7258(85)90052-X Neuss, 1987, A quantitative analysis of palliative care decisions in acute nonlymphocytic leukemia, J Am Geriatr Soc, 35, 125, 10.1111/j.1532-5415.1987.tb01341.x Petti, 1993, Pilot study of 5-aza-2′-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients, Leukemia, 7, 36 Pinto, 1993, 5-Aza-2′-deoxycytidine (decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes, Leukemia, 7, 51 Pinto, 1989, 5-Aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly, Bone Marrow Transplant, 4, 28 Pulsoni, 2004, Survival of elderly patients with acute myeloid leukemia, Haematologica, 89, 296 Richel, 1991, The antileukaemic activity of 5-Aza-2-deoxycytidine (Aza-dC) in patients with relapsed and resistant acute leukaemia, Br J Cancer, 64, 144, 10.1038/bjc.1991.258 Ries, 2003 Rivard, 1981, Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia, Leuk Res, 5, 453, 10.1016/0145-2126(81)90116-8 Rüter, 2004, DNA methylation as a therapeutic target in hematologic disorders, Int J Hematol, 80, 128, 10.1532/IJH97.04094 Saba, 2004, First report of the phase III North American trial of decitabine in advanced myelodysplastic syndrome (MDS), Blood, 104, 64, 10.1182/blood.V104.11.67.67 Santini, 2001, Changes in DNA methylation in neoplasia, Ann Intern Med, 134, 573, 10.7326/0003-4819-134-7-200104030-00011 Schmelz, 2005, Induction of gene expression by 5-aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms, Leukemia, 19, 103, 10.1038/sj.leu.2403552 Schwartsmann, 1997, Decitabine (5-aza-2′-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia, Leukemia, 11, S28 Tallman, 2002, All-trans retinoic acid in acute promyelocytic leukemia, Blood, 100, 4298, 10.1182/blood-2002-02-0632 Taylor, 1995, De novo acute myeloid leukaemia in patients over 55-years-old, Leukemia, 9, 231 Toyota, 2001, Methylation profiling in acute myeloid leukemia, Blood, 97, 2823, 10.1182/blood.V97.9.2823 Vey, 2004, The benefit of induction chemotherapy in patients age > or = 75 years, Cancer, 101, 325, 10.1002/cncr.20353 Wahlin, 1991, Remission rate and survival in acute myeloid leukemia, Eur J Haematol, 46, 240, 10.1111/j.1600-0609.1991.tb00547.x Widschwendter, 2001, Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer, J Mammary Gland Biol Neoplasia, 6, 193, 10.1023/A:1011360724350 Wijermans, 1997, Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome, Leukemia 11, S19 Wijermans, 2000, Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome, J Clin Oncol, 18, 956, 10.1200/JCO.2000.18.5.956 Willemze, 1997, A randomized phase II study on the effects of 5-aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia, Leukemia, 11, S24 Willemze, 1993, Preliminary results with 5-aza-2′-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group, Leukemia, 7, 49